All posts by imreal

Julia Sweeney is Named President of Infolinx System Solutions


Julia Sweeney, President of Infolinx

Infolinx has thrived under Julia’s leadership and I know that she is the right leader for this team.

Infolinx, a division of Spacesaver Interiors, today announced that Julia Sweeney has been named President of Infolinx. Sweeney previously held the position of Vice President of Infolinx, serving as leader of the business unit.

“Infolinx has thrived under Julia’s leadership and I know that she is the right leader for this team.” said CEO Amy Hamilton. “She is a proven leader with a winning combination of strategic sales acumen, business process improvement, and team development. Her vision for strategic growth and a customer-first approach is exactly what Infolinx needs as it enters its next phase of product innovation and growth.”

Julia has over 30 years of strategic growth and sales experience from her previous senior executive roles at global Fortune 500 companies. Her industry knowledge and proven ability to build high-performing teams will be key to positioning Infolinx for growth in new and existing verticals.

Since joining Infolinx in Q4 of 2018, Julia has spearheaded significant strategy shifts, with a strong focus on better aligning proven technology with the needs of today’s organizations. Under Julia’s leadership, the company surpassed its sales projections, secured compliance with current regulatory requirements and increased its portfolio of enterprise customers.

“During my first year with Infolinx, we made tremendous progress,” said Julia. “From new product development processes, to re-focusing investments in our marketing strategy and establishing strong organizational security policies – all while delivering revenue growth. I also focused on ensuring that our team was aligned with our strategic goals as well as fostering a strong sense of collaboration. Looking ahead, my goals include continuing the drive for revenue growth and accelerating our ability to innovate as a company.”

Founded in 1987, Infolinx, a division of Spacesaver Interiors, is a leading provider of records and information management software. Infolinx provides a streamlined solution for managing records and information at any scale to meet the compliance and information governance needs of today’s organizations.

About Infolinx:

As a leading provider of records and information management software, Infolinx enables organizations to track and manage the complete lifecycle of important physical and digital records. From record creation to disposition, Infolinx provides a streamlined solution for managing records and information at any scale to meet the compliance and information governance needs for today’s modern workplace. Apply lifecycle rules or legal holds, secure access at any level, and create workflow approvals – all with a legally defensible audit trail. Available in the cloud or on-premises, Infolinx is scalable, 100% browser-based and implemented across several industry verticals including healthcare, pharmaceutical, government, financial services, and education. To learn more, visit infolinx.com.

About Spacesaver Interiors:

Spacesaver Interiors is a full-service commercial dealer representing over 70 quality manufacturers who share our commitment to sustainability, quality and customer service within the Washington metropolitan area. Clients come to Spacesaver Interiors when they need comprehensive, highly functional, and creative workplace solutions. Whether they require storage and furniture solutions or business services, we provide them with the highest level of service and experience in the business. To learn more, visit spacesaverinteriors.com.

Share article on social media or email:

Applications of High Throughput Gene Expression Profiling in Early Drug Discovery, Upcoming Webinar Hosted by Xtalks


Xtalks Life Science Webinars

In this webinar, a workflow will be presented for the processing of 384 cell lysates with RNA-seq to generate expression data analyzed at the pathway level.

Early stages of drug discovery often depend on relatively simple reporter assays or phenotypic readouts, providing little or no information on the drug’s mechanism of action (MOA). Gene expression profiling technologies like RNA sequencing (RNA-seq) enable a more comprehensive characterization of compounds by measuring the activity of molecular pathways. This information can complement phenotypic readouts and can be used to prioritize candidate compounds for further testing. RNA expression profiling also serves as a generic test that can be applied to any drug development pipeline without the need for target-dependent customization.

In this webinar, a workflow will be presented for the processing of 384 cell lysates with RNA-seq to generate expression data analyzed at the pathway level. The data show that shallow sequencing of crude cell lysates reproducibly detects over 5000 genes with at least ten reads. Subsampling of deep sequencing datasets demonstrated that differential pathway analysis is largely unaffected when reducing the number of genes to this level. Consequently, reliable pathway insights can be obtained at high throughput and relatively low cost while not being limited to a predefined set of genes or pathways.

In cell perturbation screenings (small molecules, RNAi, antisense or CRISPR), the application can provide in-depth information on the mode of action underlying the induced cellular phenotypes as well as molecular similarity scores to identify those perturbations acting similar to a reference condition or via shared molecular mechanisms. This methodology can also be applied to repurpose off-target siRNA hits from library screens to reveal novel candidate therapeutic targets for drug development.

Join Pieter Mestdagh PhD, Senior Scientist, Biogazelle in a live webinar on Wednesday, May 27, 2020 at 9am EDT (2pm BST/UK).

For more information or to register for this event, visit Applications of High Throughput Gene Expression Profiling in Early Drug Discovery.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

Telehealth Thrives Amid Social Distancing, COVID-19 Crisis


Kalorama Information logo

RPM and telehealth was still trying to persuade buyers of the usefulness, the business case when COVID-19 hit. Those conversations have been made easier, and we’ve even heard that POs that were pending hospital approval have been rushed through.

COVID-19 has forced the separation of healthcare providers from patients in many cases, making the case for remote patient monitoring and telehealth systems. The global patient monitoring and telehealth market is estimated to be worth about $42 billion in 2019, inclusive of devices, peripherals, software, packaged services, monitoring services and other applications, according to a report from Kalorama Information, part of Science and Medicine Group, a market research firm.

“RPM and telehealth was still trying to persuade buyers of the usefulness, the business case when COVID-19 hit,” said Bruce Carlson, Publisher of Kalorama Information. “Those conversations have been made easier, and we’ve even heard that POs that were pending hospital approval have been rushed through.”

Temporarily, restraints due to HIPPA legislation have been lifted. The Office for Civil Rights (OCR) at the Department of Health and Human Services (HHS) is responsible for enforcing certain regulations issued under the Health Insurance Portability and Accountability Act of 1996 (HIPAA) indicated that “A covered health care provider that wants to use audio or video communication technology to provide telehealth to patients during the COVID-19 nationwide public health emergency can use any non-public facing remote communication product that is available to communicate with patients.”

No longer is telehealth for rural patients alone. Legislation from the House details that for qualified providers, an emergency waiver will allow telehealth to be reimbursed by Medicare.

The interest in telemedicine and telehealth has exploded over the last decade. Involvement in this care segment has several benefits and hospitals, caregivers, device manufacturers, and patients are continuing to jump on board with acceptance using this technology. There are more than 700 clinical trials using telehealth recently completed, currently underway. The global patient monitoring and telehealth market has continued its expansion in both the institutional and home segments of the health market with the United States and many European countries at the forefront of implementation.

Among the trends Kalorama analysts have noticed recently include the following:

  • – Increasing demand and business opportunities as a result of COVID-19.
  • – Pending POs for telehealth equipment and services that hospitals were delaying being completed as a response to COVID.
  • – Companies are facing growing difficulties in accessing supplies to provide monitoring equipment.
  • – Companies are experiencing longer lead times for manufacturing monitoring equipment.
  • – Companies have had to expand capacity for surges in use; one company reported a move to a hosting platform that could handle the increased volume – a move that has not come without several hurdles to implement.
  • – Most companies report increased and enhanced security software upgrades.
  • – Still uncertainty if widespread telehealth reimbursement and other implemented programs will sustain post-COVID.
  • – Inquiries, New Orders are up

Kalorama Information’s Remote Patient Monitoring report details the companies in the market and the size of the market by application. It can be found at: https://kaloramainformation.com/product/remote-patient-monitoring-and-telehealth-market/

About Kalorama Information

For more than 30 years, Kalorama Information has been a leading publisher of market research in healthcare areas, including in vitro diagnostics (IVD), biotechnology, healthcare, medical devices, and pharmaceuticals.

Share article on social media or email:

Critical Alert Achieves FDA Clearance as a Class II Medical Device for its CommonPath Enterprise Software


News Image

This FDA clearance is the culmination of years of work reshaping the scale of our core product and completely alters the trajectory of Critical Alert

Critical Alert, a leading provider of enterprise-class patient communications software for hospitals and healthcare systems, announced today it has been granted FDA clearance for its CommonPath Enterprise software platform as a Class II Medical Device. The platform provides the intelligent routing of patient events and medical device alarms with robust analytics on a single enterprise platform.

CommonPath Enterprise, architected to be centrally configured and managed from a single data center, can be deployed across any size healthcare enterprise. The SaaS platform includes support for UL-1069 nurse call with the native ability to use any third-party call light hardware, medical devices, and clinical communication & collaboration platforms.

“This clearance is the culmination of years of work reshaping the scale of our core product and completely alters the trajectory of Critical Alert,” said April Hjort, vice president of research and development at the company. “Our current and future customers will benefit from this commitment to innovation and interoperability. I am proud to have been part of this transformation and excited to see the adoption of our innovative approach in the marketplace,” continued Hjort.

CommonPath Enterprise transforms a disparate patient communication ecosystem into a connected, real-time health system enabling caregivers to provide more efficient and informed responses to patient needs and safety. It also empowers leadership with intuitive easy-to-configure workflow and analytics software for continuous improvement of processes.

“CommonPath Enterprise is unique in the nurse call industry in that, as a software-based platform, it can function on our signaling equipment, as well as that made by third-party manufacturers, breathing new life into legacy systems without turning a system upgrade into a construction project,” stated John Elms, CEO at Critical Alert. “With FDA clearance, we can now bring convergence to physical requests from the patients with physiological needs communicated by connected medical devices on the same modern and cybersecure platform,” continued Elms.

About Critical Alert

Critical Alert offers a cost-effective solution set of enterprise-class, software-based products, services and strategies that enable hospitals and healthcare enterprises to give patients a voice, empower clinical staff with actionable intelligence, and unburden their support and IT teams. CommonPath Enterprise, our software-driven patient communications platform, is FDA-cleared as a Class II Medical Device and includes UL-1069 nurse call, overlay software to modernize legacy nurse call systems, alarm management & event notification, patient experience monitoring, advanced clinical analytics, and a portfolio of integrated partner offerings.

For more information, visit: http://criticalalert.com/alarm-management/ and follow on LinkedIn.

Critical Alert is a trademark of Critical Alert. All other product or service names are the property of their respective owners.

Share article on social media or email:

Biocompare Launches Workflow Optimization Content Hub for Life Scientists


Future Lab: Optimizing Workflows in the Life Science Lab

Future Lab: Optimizing Workflows in the Life Science Lab

Finding the right lab equipment can be really challenging and I see Future Lab as an amazing opportunity to simplify this journey by providing our expertise on the lab tools and technologies in a way that the scientist can immediately adopt to their work.

In collaboration with Sartorius, Biocompare has introduced a new content hub called Future Lab: Optimizing Workflows in the Life Science Lab. The comprehensive information source was created for life scientists to help them optimize workflows in their lab, from water purification and liquid handling to contamination control.

The content hub features the latest guidance about enabling tools and technologies, the best ways to streamline workflows, and practical tips from experts. With Sartorius as its sponsor, Optimizing Workflows in the Life Science Lab will deliver the essential information scientists need to improve laboratory operations so they can spend more time on their research.

Future Lab is an interactive information resource designed to showcase the latest breakthroughs, trends, news, and products within specific scientific niches. Since their launch four years ago, Future Lab content hubs have become invaluable resources for life scientists around the world. The hubs are updated weekly, and regular alerts drive engagement with registered users.

“We are really excited to have developed this platform to allow the more than 3.3 million scientists who visit Biocompare each year to consume content in a much more engaging environment. This fully supports Biocompare’s mission to educate scientists in the latest technology while providing the tool provider community a unique and novel way to engage with our audience,” says Joan Boyce, VP & GM of Biocompare.

Previous Future Labs have focused on other integral topics in life science research including Next-Gen Sequencing, Functional Genomic Screening, Automated Sample Prep, Antibody Therapeutics, Genetic Analysis, Live Cell Imaging, Protein Production, Immunodetection, Cell Culture, Liquid Handling, Flow Cytometry, and Biopharmaceutical Analysis.

“Researchers should have a chance to focus their time and efforts on science. Finding the right lab equipment can be really challenging and I see Future Lab as an amazing opportunity to simplify this journey by providing our expertise on the lab tools and technologies in a way that the scientist can immediately adopt to their work,” added Emilia Varhimo, Head of Product Management, Pipetting & Dispensing at Sartorius.

About Biocompare

Biocompare, a Division of CompareNetworks, Inc., is the leading resource for up-to-date product information, product reviews, and new technologies for life scientists. Biocompare combines an in-depth knowledge of life science products and new technologies with the power of the Internet to offer scientists the most dynamic, relevant, and innovative resource that enables them to make better products, technology, and service purchasing decisions. Produced by scientists, Biocompare’s mission is to provide free, time-saving services to life science researchers, allowing scientists to find and learn about the technologies that drive discovery. Biocompare continually strives to serve the life science community by providing new and improved online services that facilitate product discovery and technology education. For more information, please visit http://www.biocompare.com.

Share article on social media or email:

NeoTract Designates Dr. Ali Sarram as UroLift® Center of Excellence


News Image

“This designation recognizes Dr. Ali Sarram as a UroLift Center of Excellence for his commitment to providing safe and effective treatment to patients with BPH,” said Dave Amerson

NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced that Ali Sarram M.D., Colorado Urology in Parker, CO, has been designated as a UroLift® Center of Excellence. The designation recognizes that Dr. Sarram has achieved a high level of training and experience with the UroLift® System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with Benign Prostatic Hyperplasia (BPH), also known as enlarged prostate.

Recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines, the FDA-cleared Prostatic Urethral Lift procedure using the UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to BPH. The UroLift permanent implants, delivered during a transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue.

The UroLift Center of Excellence program is designed to highlight urologists who are committed to educating their patients on BPH and the UroLift System as a treatment option and consistently seek to deliver excellent patient outcomes and experiences.

“This designation recognizes Dr. Ali Sarram as a UroLift Center of Excellence for his commitment to providing safe and effective treatment to patients with BPH,” said Dave Amerson, president of the Teleflex Interventional Urology business unit. “We are pleased to see the continued acceptance of the UroLift System as a standard of care treatment that may allow men to discontinue the use of BPH medications and improve their quality of life.”

Over 40 million men in the United States are affected by BPH, a condition that occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems and can cause loss of productivity, depression and decreased quality of life.

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction, and retrograde ejaculation.

About the UroLift® System

The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function*1,2. Patients also experienced a significant improvement in quality of life. Over 100,000 men have been treated with the UroLift System in the U.S. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The Prostatic Urethral Lift procedure using the UroLift System is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at http://www.UroLift.com.

About NeoTract | Teleflex Interventional Urology

A wholly owned subsidiary of Teleflex Incorporated, the Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function*1,2. Learn more at http://www.NeoTract.com.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit http://www.teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a common sense of purpose

# # #

For Teleflex Incorporated:

Jake Elguicze, 610.948.2836

Treasurer and Vice President, Investor Relations

Media:

Nicole Osmer, 650.454.0504 nicole@healthandcommerce.com

*No instances of new, sustained erectile or ejaculatory dysfunction

1. Roehrborn, J Urology 2013 LIFT Study

2.McVary, J Sex Med 2016

MAC00968-01 Rev A

Share article on social media or email:

Acer’s Newest ConceptD Monitor Offers Creators Outstanding Clarity and Color Accuracy in a Beautiful Design


The ConceptD CM2241W offers superb color accuracy and fast performance in a striking design for $399.99 MSRP.

The ConceptD CM2241W leverages an incredibly fast 1ms response time to support clear images and 99 percent RGB coverage to deliver bright, lifelike and professional grade colors.

Editor’s Summary:


  • ConceptD CM2241W is a new 24-inch HD (1920×1200) monitor for creative professionals
  • Provides excellent color accuracy covering 99 percent of the Adobe RGB color gamut
  • Delivers superb color reproduction with a low Delta E less than 2 rating
  • PANTONE® Validated panel features integrated color correction and fidelity
  • Fast 1ms visual response boost (VRB) facilitates clear, blur-free visuals

Acer America announced its newest ConceptD monitor for creative professionals is now available in the United States. The ConceptD CM2241W offers superb color accuracy and fast performance in a striking design for $399.99 MSRP.

Creators in the visual arts, such as graphic designers and photographers, require a monitor that can quickly and smoothly perform tasks with a wide and accurate color range. The ConceptD CM2241W leverages an incredibly fast 1ms response time to support clear images and 99 percent RGB coverage to deliver bright, lifelike and professional grade colors. PANTONE® validated, this display offers integrated color correction and superior fidelity in reproducing PANTONE Matching System (PMS) colors. Tested and calibrated to a low Delta E less than 2 rating means color reproduction is so accurate, differences are barely perceptible to the human eye.

“The ConceptD CM2241W provides creative professionals high color accuracy and a wide color range to assist them in creating visuals that are true to life,” said Ronald Lau, Acer America director – stationary computing. “To ensure viewing comfort for long work sessions, it’s supported by an ergonomic stand with a range of adjustment options and provides wide viewing angles.”

The 1920 x 1200 resolution and 16:10 aspect ratio with up to a 75Hz response time provides sharp visuals for creating graphics and editing photos. Featuring an IPS panel, the ConceptD CM2241W provides wide 178 degree viewing angles. A 350 nits brightness and 100,000,000:1 max contrast ratio infuse images with brilliant color and clarity and support the DCI-P3, sRGB, AdobeRGB, the Rec. 709 HDTV and SMPTE-C broadcasting standards.

The integrated Acer Display Widget simplifies setting modification for creating a profile, organizing the viewing space via screen split and customizing settings for each application. An ergonomic stand supports viewing comfort with pivot, –5 to 35 degree tilt, 360° swivel and up to 4.7 inch height adjustment. A quick-release design easily disconnects the monitor from its stand for VESA wall-mounting to maximize desk space. Handy cable management helps keep the work area tidy, while excellent connectivity includes two HDMI (1.4) ports, DisplayPort and three USB 3.0 ports.

The ConceptD CM2241W monitor is outfitted with two 2W speakers and available at leading retailers now with prices starting at $399.99 MSRP.

Acer displays are backed by professional, high-quality technical support and a standard three-year parts and labor warranty.* Acer’s online community at community.acer.com provides customers discussion forums, answers to frequently asked questions and the opportunity to share ideas for new and enhanced services and products.

About Acer

Founded in 1976, today Acer is one of the world’s top ICT companies and has a presence in over 160 countries. As Acer looks into the future, it is focused on enabling a world where hardware, software and services will infuse with one another to open up new possibilities for consumers and businesses alike. From service-oriented technologies to the Internet of Things to gaming and virtual reality, Acer’s 7,000+ employees are dedicated to the research, design, marketing, sale, and support of products and solutions that break barriers between people and technology. Please visit http://www.acer.com for more information.

Media Contact

Erin Davern        

Tel: +949-471-7785    

Email: erin.davern@acer.com

© 2020 Acer America Corp. All rights reserved. Acer and the Acer logo are registered trademarks of Acer Inc. Other trademarks, registered trademarks, and/or service marks, indicated or otherwise, are the property of their respective owners. All offers subject to change without notice or obligation and may not be available through all sales channels. Prices listed are manufacturer suggested retail prices and may vary by location. Applicable sales tax extra.

  • Limited warranty agreement applies. For a copy, write to Acer Customer Service, P.O. Box 6137, Temple, TX 76503.

Share article on social media or email:

CDC Awards Contract to the American College of Medical Toxicology to Obtain Critical Drug Overdose Data from the Toxicology Investigators Consortium


Toxicology Investigators Consortium

“Particularly now, in the midst of the opioid overdose epidemic we anticipate this collaboration will deliver critical data that could improve public health decision making.” -Dr. Paul Wax, Executive Director, ACMT

ACMT’s ToxIC is a unique multicenter toxico-surveillance and research network comprised of physicians specifically qualified in the field of medical toxicology. Since the network’s establishment in 2010, there have been over 73,000 cases recorded into ToxIC’s Patient Registry from 40 participating sites across the United States comprised of more than 60 hospitals and clinics. This registry was designed to provide accurate and reliable data on overdose and adverse effects arising from exposures to medications, drugs of abuse, natural substances, metals, pesticides, or other chemical substances.

“ACMT is very honored to receive this contract from CDC for this important project related to drug overdose surveillance,” said Dr. Paul M. Wax, ACMT’s Executive Director and co-founder of ToxIC. “For over a decade, ACMT has worked diligently to develop the ToxIC Patient Registry as a useful tool for overdose surveillance. Particularly now, in the midst of the opioid overdose epidemic we anticipate this collaboration will deliver critical data that could improve public health decision making.”

This collaboration is expected to help CDC better characterize drug overdose and is consistent with the CDC’s mission to provide leadership in preventing and controlling injuries.

The American College of Medical Toxicology (ACMT) is a professional, nonprofit association of physicians with recognized expertise and board certification in medical toxicology. Our members specialize in the prevention, evaluation, treatment, and monitoring of injury and illness from exposures to drugs and chemicals, as well as biological and radiological agents. ACMT members work in clinical, academic, governmental, and public health settings, and provide poison control center leadership.

Share article on social media or email:

Crum & Forster Pet Insurance Group™ Supports Human-Animal Bond Research


News Image

Pet health insurance plays a key role in strengthening the human-animal bond and supporting the needs of our furry family members…” said Steve Feldman, HABRI Executive Director.

The Human Animal Bond Research Institute (HABRI) announced today that Crum & Forster Pet Insurance Group™, one of the oldest U.S. providers of pet health insurance, has become an official supporter of HABRI and its research on the human health benefits of companion animals.

“For twenty years, we’ve been committed to helping people get access to reliable and affordable pet insurance coverage,” said Bob Capobianco, Senior Vice President, Crum & Forster Pet Insurance Group. “Supporting HABRI research is important because it connects the positive impact that pets play in our lives, and closely aligns with the work we do to help pets live longer and healthier.”

“HABRI is thrilled to welcome Crum & Forster Pet Insurance Group as a supporter,” said Steven Feldman, Executive Director of HABRI. “From HABRI research, we know that pets are considered part of the family, and that the growing importance of pets in our lives has driven demand for pet-inclusive policies and benefits at home, in the workplace, and beyond. Pet health insurance plays a key role in strengthening the human-animal bond and supporting the needs of our furry family members, and HABRI is thrilled to be working with Crum & Forster to help more people and pets benefit from healthy human-animal bonds.”

Scientific evidence increasingly shows that pets improve heart health, alleviate depression, increase well-being, support child health and development, and contribute to healthy aging. In addition, companion animals can assist in the treatment of a broad range of conditions from post-traumatic stress to Alzheimer’s disease to autism spectrum disorder.

The benefits of the human-animal bond impact more than just human health. Findings from a recent HABRI survey of 2,000 pet owners demonstrate that knowledge of the scientific research on the human-animal bond motivates pet owners to take better care of their pets. From providing pets with higher quality nutrition to purchasing pet health insurance, spreading awareness of the health benefits of pet ownership improves pet health and welfare.

“Crum & Forster Pet Insurance Group is dedicated to meeting the needs of our clients, and from HABRI research we know the overwhelming majority of pet-owners view their pets as close members of the family,” added Capobianco. “We look forward to supporting HABRI research and helping discover even more ways pets enrich our lives.”

About Crum & Forster Pet Insurance Group™

Crum & Forster Pet Insurance Group (C&F Pet) is committed to helping pet parents get access to reliable and affordable pet health insurance plans. With a history dating back to 1997, making it one of the original providers in the U.S., C&F Pet utilizes various go-to-market strategies, including direct-to-consumer, employee benefits, white labels, and other partnerships. Insurance plans are underwritten by United States Fire Insurance Company and produced by C&F Insurance Agency, Inc. (NPN # 3974227), a Crum & Forster company. More information can be found at http://www.cfpetinsurance.com.

Crum & Forster Pet Insurance Group, Crum & Forster, and C&F are registered trademarks of United States Fire Insurance Company. Crum & Forster is comprised of leading and well-established property and casualty business units.

The Human Animal Bond Research Institute (HABRI) is a not-for-profit organization that maintains the world’s largest online library of human-animal bond research and information; funds innovative research projects to scientifically document the health benefits of companion animals; and informs the public about human-animal bond research and the beneficial role of companion animals in society. For more information about the HABRI Foundation, please visit http://www.habri.org.

Share article on social media or email:

New Assay Kits from Salimetrics Confirm Integrity of Oral Fluid/Saliva Samples for Use in Serological Studies of Specific Infectious Diseases (COVID-19)


Saliva as a non-invasive approach to monitoring immune status has the benefits of increasing participant compliance as well as the speed of sampling anywhere, anytime.

Now in the early phase of the COVID-19 pandemic, verification of the integrity of public surveillance and testing is critical. Saliva and oral fluids are increasingly seen as minimally invasive alternatives to traditional biospecimens (e.g., nasal swabs, blood sampling). Saliva can be easily and safely self-collected while social distancing or “stay-at-home” restrictions are in place, and thus saliva/oral fluid sampling provides an opportunity for large-scale community surveillance. As any pandemic evolves, community-based seroprevalence studies to determine who has been and who has not been exposed is of the utmost importance. Tests that make these determinations must be scalable at a population level and have the lowest possible rates of false positives and negatives.

Recently, Salimetrics announced two new salivary assay kits to be employed when oral fluid/saliva specimens are used for this purpose – the Salivary Total Human IgG ELISA Kit (Cat. No. 1-4502) and the Salivary Total Human IgM ELISA Kit (Cat. No. 1-4002). Both assays come in a 96-well microtiter plate format, require low sample volumes, are fast, and amenable to high throughput batch processing. These assays assure the quality of oral fluid/saliva samples and therefore improve specificity and sensitivity of corresponding pathogen-specific serological assays. Specifically, these assay tools minimize false negative determinations in pathogen-specific serological assays by excluding samples that have insufficient total antibody. Researchers can safely collect samples using SalivaBio’s FDA listed oral fluid/saliva collection devices that have been optimized for ease of collection from participants as well as downstream processing of samples in the lab.

The utility of Salimetrics Human Total IgG and Total IgM Assay Kits is realized when investigating the immune status of an individual to a specific pathogen by assessing IgG or investigating recent pathogen exposure in an outbreak situation by assessing IgM. “Since IgG/IgM levels vary between individuals and individual samples, and the primary source of these antibodies is serum, researchers must qualify an oral fluid sample for total IgG/IgM to determine if enough IgG/IgM is present to further qualify a positive or negative disease target,” says Steve Granger, Ph.D., Salimetrics CSO. “These assays can be utilized as companion tests with disease-specific target assays (such as COVID-19) on the same sample.” By determining the disease-specific antibodies present in relation to the total IgG/IgM, researchers can form reliable thresholds to indicate positive or negative results.

In saliva, IgG/IgM passively diffuses through the gingival crevicular epithelium, where samples can be conveniently collected. “Since IgG/IgM in saliva is bioidentical to its serum counterparts, researchers will find it a valuable alternative to blood sampling. Saliva as a non-invasive approach to monitoring immune status has the benefits of increasing participant compliance as well as the speed of sampling anywhere, anytime,” says Granger. “This can be advantageous during an epidemic, natural disaster, or for general epidemiological research.”

Salimetrics continues to be a key partner in bringing best-in-class solutions to salivary bioscience research. By using Salimetrics, researchers can find and implement solutions where the full potential of salivary measures have yet to be realized. To learn more about the new Salivary Total Human IgG and IgM Assay Kits, as well as the available FDA listed oral fluid/saliva collection devices, researchers can visit the Salimetrics Website, or contact researcher support to integrate total salivary IgG/IgM into their current or future research study.

About Salimetrics

Salimetrics’ assay kits and CLIA-certified testing services are used to measure salivary analytes related to stress, behavior and development, inflammation, sleep, reproduction, health and immune function. Founded in 1998 by Douglas A. Granger, Ph.D., Salimetrics, LLC support CROs, pharmaceuticals, academic researchers and the immunodiagnostic industry around the world with innovative immunoassay products, non-invasive saliva collection methods, and laboratory testing services.

Share article on social media or email: